Primary Mediastinal Large B-cell Lymphoma : Impact of Chemotherapy Choice.

Q1 Medicine

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-23 DOI:10.1016/j.hemonc.2021.05.002

Rehab Elhagracy, Abdulaziz Hamadah, Karen Pinto, Amany Hussain, Mohammad Osmani, Salem Alshemmari

{"title":"Primary Mediastinal Large B-cell Lymphoma : Impact of Chemotherapy Choice.","authors":"Rehab Elhagracy, Abdulaziz Hamadah, Karen Pinto, Amany Hussain, Mohammad Osmani, Salem Alshemmari","doi":"10.1016/j.hemonc.2021.05.002","DOIUrl":null,"url":null,"abstract":"Objective/background: Data generated from retrospective studies on primary mediastinal B-cell lymphoma (PMBCL) outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma.Methods: Our goal was to assess the long-term outcome of 41 patients with PMBCL who were treated at the Kuwait Cancer Center. We evaluated two types of multidrug treatment, R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone) and DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), and determined overall survival and complete response (CR) as primary endpoints.Results: In our cohort, 27 (66%) cases were treated with R-CHOP and 14 (34%) cases were treated with DA-EPOCH-R. The overall median follow-up time was 34 months. Among the patients treated with R-CHOP, 23 out of 27 (92.6%) patients achieved CR; similarly, 10 out of 14 patients (85.7%) in the DA-EPOCH-R group achieved CR after initial treatment. There were no differences in OS between patients treated with R-CHOP versus DA-EPOCH-R.Conclusion: The findings of this study indicate that combined chemotherapy and immunotherapy results in excellent long-term outcome of patients with PMBCL. At our center, we prefer R-CHOP to DA-EPOCH-R for low-risk patients with nonbulky disease.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 4","pages":"196-200"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2021.05.002","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.hemonc.2021.05.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Objective/background: Data generated from retrospective studies on primary mediastinal B-cell lymphoma (PMBCL) outcome are valuable as no prospective phase 3 trials have been conducted in this rare type of lymphoma.

Methods: Our goal was to assess the long-term outcome of 41 patients with PMBCL who were treated at the Kuwait Cancer Center. We evaluated two types of multidrug treatment, R-CHOP (rituximab, vincristine, doxorubicin, cyclophosphamide, and prednisone) and DA-EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab), and determined overall survival and complete response (CR) as primary endpoints.

Results: In our cohort, 27 (66%) cases were treated with R-CHOP and 14 (34%) cases were treated with DA-EPOCH-R. The overall median follow-up time was 34 months. Among the patients treated with R-CHOP, 23 out of 27 (92.6%) patients achieved CR; similarly, 10 out of 14 patients (85.7%) in the DA-EPOCH-R group achieved CR after initial treatment. There were no differences in OS between patients treated with R-CHOP versus DA-EPOCH-R.

Conclusion: The findings of this study indicate that combined chemotherapy and immunotherapy results in excellent long-term outcome of patients with PMBCL. At our center, we prefer R-CHOP to DA-EPOCH-R for low-risk patients with nonbulky disease.

查看原文本刊更多论文

原发性纵隔大b细胞淋巴瘤:化疗选择的影响。

目的/背景:原发性纵隔b细胞淋巴瘤(PMBCL)预后的回顾性研究数据是有价值的，因为这种罕见类型的淋巴瘤尚未进行前瞻性3期试验。方法:我们的目标是评估在科威特癌症中心接受治疗的41例PMBCL患者的长期预后。我们评估了两种多药治疗，R-CHOP(利妥昔单抗、长春新碱、多柔比星、环磷酰胺和强的松)和DA-EPOCH-R(依托泊苷、强的松、长春新碱、环磷酰胺、多柔比星和利妥昔单抗)，并确定了总生存期和完全缓解(CR)作为主要终点。结果:在我们的队列中，27例(66%)患者接受R-CHOP治疗，14例(34%)患者接受DA-EPOCH-R治疗。总体中位随访时间为34个月。在接受R-CHOP治疗的患者中，27例患者中有23例(92.6%)达到CR;同样，DA-EPOCH-R组14例患者中有10例(85.7%)在初始治疗后达到CR。R-CHOP与DA-EPOCH-R治疗患者的OS无差异。结论:本研究结果表明，化疗和免疫治疗联合治疗PMBCL患者的长期预后良好。在我们的中心，对于低风险的非大体积疾病患者，我们更倾向于R-CHOP而不是DA-EPOCH-R。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.